CBio Limited
is an Australian company with a global focus. With a vision to improve patient lives, CBio is focused on developing new generation products for the treatment of autoimmune and inflammatory diseases.

CBio was established in 2000 to develop and commercialise treatments for autoimmune diseases. In 2001, extended preclinical studies at the University of Queensland concluded that a heat shock protein identified as chaperonin 10 played a key role in down-regulating the innate immune response in patients during pregnancy. Further research suggested that chaperonin 10 appeared to intercede at a very early stage of the inflammatory process to prevent the over-expression of pro-inflammatory cytokines. Based on this research, CBio acquired a worldwide exclusive licence for the chaperonin 10 intellectual property, and now has clinical data and a robust IP portfolio surrounding the technology.

The registered trademark for CBio's patented lead molecule is XToll.






Subscribe to email alerts